ConjuChem is a research based biotechnology company that applies its proprietary in vivo bioconjugation technology to improve the therapeutic potential of peptides and small molecules.
Founded in 1997 as RedCell, ConjuChem Biotechnologies ("ConjuChem" or the "Company") is a publicly traded Canadian biotechnology company dedicated to the discovery of novel therapeutics with an initial focus on diabetes. The company is focused on discovering and developing new drugs based on its novel technology platforms called Drug Affinity Complex (DACTM) and Preformed Conjugate-Drug Affinity Complex (PC-DACTM).
Deals
To view this information, you must subscribe to PL Intelligence.
Senior management
To view this information, you must subscribe to PL Intelligence.
Board of directors
To view this information, you must subscribe to PL Intelligence.
Contact details
To view this information, you must subscribe to PL Intelligence.
Head office
ConjuChem Biotechnologies
225 President Kennedy Avenue
Suite 3950, 3rd Floor
Montreal
Quebec
H2X 3Y8 Quebec
All rights reserved. Terms and Conditions | Contact us
